Description
Kipferon Pharmacological action.
– immunomodulatory;
– antiviral;
– antichlamydial.
Pharmacological properties.
Kipferon®” suppositories is a complex dosage form containing human recombinant interferon-?2 and a complex immunoglobulin preparation (CIP). Interferon-?2 is an activator of innate and acquired immunity, has a pronounced antiviral activity, enhances protection against viral, chlamydial, mycoplasma and bacterial infections, has an immunomodulatory effect in the development of immunological reactions, promotes the growth and preservation of normoflora of the intestine and the vagina. The biological activity of interferon-?2 is realized through interaction with the receptor apparatus of immunocompetent and other cells, resulting in increased expression of HLA I and HLA II molecules on the surface of all types of cells and regulation of cell cooperation, increasing the activity of natural killer cells and giving intact cells resistance against their cytolytic action, proliferation of CD8 T-cells. Increases the production of gamma-interferon by natural killer cells. Complex immunoglobulin preparation KIP contains specific and non-specific immunoglobulins of classes G, M, A. The combination of anti-viral, anti-chlamydial, antibacterial and antitoxic antibodies belonging to different classes of immunoglobulins provides agglutination, neutralization and precipitation of etiotropic pathogenic agents. In the place of application it provides stabilization of interferon from mucous membrane secretions, normalizes local immunity due to inflow of IgA and IgM with suppositories (substitution effect), increases activity of locally produced cytokines.
Indications
The drug is used in the treatment of diseases accompanied by secondary immunodeficiency states:
– Acute respiratory diseases, inflammatory diseases of the oropharynx of bacterial and viral etiology in children and adults;
– Acute viral (rotavirus) and bacterial (salmonellosis, dysentery, coli-infection) intestinal infections, including with manifestations of intestinal dysbacteriosis of varying severity in children;
– urogenital chlamydia in women (including pregnant women in the II-III trimesters of pregnancy), including vaginal dysbacteriosis, vulvovaginitis, cervicitis uteri, cervical erosions.
Contraindications
Individual intolerance to the individual components, pregnancy I trimester, lactation.
Directions for use and dosages
- “Kipferon ®” is used rectally and vaginally. The drug is used in combination with conventional means of pathogenetic therapy of infectious diseases, as well as antibiotics for indications. The method and mode of dosing, as well as its use in combination therapy is determined by a doctor, depending on the diagnosis, acuteness and severity of the disease.
- Acute respiratory diseases, inflammatory diseases of the oropharynx of bacterial and viral etiology: suppositories are administered rectally (mainly after the defecation act) to children under 1 year old – 1 suppository a day, children under 12 years – 1 suppository twice a day, adults and children over 12 years – 1 suppository three times a day. The prescription of “Kipferon®” is the most effective and reasonable in the acute phase of the disease (preferably during the first 3 days). The course of treatment is determined by the etiology, the severity of the disease, the presence of concomitant complications, pathological conditions and is 5-7 days.
- Acute viral (rotavirus) and bacterial (salmonellosis, dysentery, coli-infection) intestinal infections, including with manifestations of intestinal dysbacteriosis of varying severity in children: suppositories are administered rectally (mostly after the defecation act) to children under 1 year old – one suppository daily, children under 12 years – one suppository twice daily, adults and children over 12 years – one suppository three times daily. It is most effective and expedient to prescribe the drug in the acute period of the disease (preferably in the first 3 days). The duration of the course of treatment is determined by the etiology, the form of severity of the disease, the presence of concomitant complications, pathological conditions and is 5-7 days.
- Urogenital chlamydia in women (including pregnant women in the II-III trimesters of pregnancy), including with symptoms of vaginal dysbacteriosis, vulvovaginitis, cervicitis uteri, cervical erosion: suppositories are administered deeply intravaginal (before contact with the posterior fornix and cervix) for 1-2 suppositories, depending on the severity of the disease, twice a day. The course of treatment averages 10 days; in the presence of cervical erosion the drug is continued until its epithelialization. Under indications the course of treatment may be repeated in one month. Treatment should begin in the first days after menstruation. Before introduction it is recommended to remove mucus from the mucous membranes of the vagina and cervix.
